Amphastar Pharma Valuation Multiples

Amphastar Pharma Overview

About Amphastar Pharma

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Founded

2004

HQ

Employees

2.0K

Website

amphastar.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $728M

EBITDA: $241M

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Amphastar Pharma Financials

Amphastar Pharma reported last 12-month revenue of $728M and EBITDA of $241M.

In the same LTM period, Amphastar Pharma generated $389M in gross profit, $241M in EBITDA, and $156M in net income.

Amphastar Pharma P&L

In the most recent fiscal year, Amphastar Pharma reported revenue of $720M and EBITDA of $241M.

Amphastar Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Amphastar Pharma Stock Performance

Amphastar Pharma has current market cap of $965M, and enterprise value of $1B.

Amphastar Pharma's stock price is $21.01.

Amphastar Pharma Valuation Multiples

Amphastar Pharma trades at 1.8x EV/Revenue multiple, and 5.6x EV/EBITDA.

Amphastar Pharma Financial Valuation Multiples

As of March 21, 2026, Amphastar Pharma has market cap of $965M and EV of $1B.

Equity research analysts estimate Amphastar Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Amphastar Pharma has a P/E ratio of 6.2x.

Amphastar Pharma Margins & Growth Rates

Amphastar Pharma's revenue in the last 12 month grew by 5%.

Amphastar Pharma's revenue per employee in the last FY averaged $0.4M.

Amphastar Pharma's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Amphastar Pharma's rule of X is 46% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Amphastar Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Amphastar Pharma M&A Activity

Amphastar Pharma acquired XXX companies to date.

Last acquisition by Amphastar Pharma was on XXXXXXXX, XXXXX. Amphastar Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Amphastar Pharma Investment Activity

Amphastar Pharma invested in XXX companies to date.

Amphastar Pharma made its latest investment on XXXXXXXX, XXXXX. Amphastar Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).